english

Liste des publications

Naldi A, Larive RM, Czerwinska U, Urbach S, Montcourrier P, Roy C, Solassol J, Freiss G, Coopman PJ, Radulescu O. Reconstruction and signal propagation analysis of the Syk signaling network in breast cancer cells. PLoS Comput Biol. 2017 Mar 17;13(3):e1005432. doi: 10.1371/journal.pcbi.1005432. [Epub ahead of print]

 

Vendrell JA, Mau-Them FT, Béganton B, Godreuil S, Coopman P, Solassol J. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. Int J Mol Sci. 2017 Jan 29;18(2). pii: E264. doi: 10.3390/ijms18020264. Review.

 

Belguise K, Cherradi S, Sarr A, Boissière F, Boulle N, Simony-Lafontaine J, Choesmel-Cadamuro V, Wang X, Chalbos D. PKCθ-induced phosphorylations control the ability of Fra-1 to stimulate gene expression and cancer cell migration. Cancer Lett. 2016 Nov 2. pii: S0304- 3835 (16)30669-3. doi: 10.1016/j. canlet.2016.10.038. [Epub ahead of print]

 

Frouin E, Maudelonde T, Senal R, Larrieux M, Costes V, Godreuil S, Vendrell JA, Solassol J. Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens. PLoS One. 2016 Jul 28;11(7):e0158698. eCollection 2016.

 

Mangé A, Dimitrakopoulos L, Soosaipillai A, Coopman P, Diamandis EP, Solassol J..An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma. J Proteomics. J Proteomics. 2016 May 7. [Epub ahead of print]

 

Coopman P, Djiane A. Adherens Junction and E-Cadherin complex regulation by epithelial polarity. Cell Mol Life Sci. 2016 May 5. [Epub ahead of print

 

Bach AS, Derocq D, Laurent-Matha V, Montcourrier P, Sebti S, Orsetti B, Theillet C, Gongora C, Pattingre S, Ibing E, Roger P, Linares LK, Reinheckel T, Meurice G, Kaiser FJ, Gespach C, Liaudet-Coopman E. Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells. Oncotarget. 2015 Jun 27. [Epub ahead of print].

 

Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, Schumacher U, Costes V, Maudelonde T, Pantel K, Alix-Panabières C  Establishment and characterization of a cell line from human circulating colon  Cancer cells.Cancer Res. 2015 Mar 1;75(5):892-901

 

Bourgier C, Lacombe J, Solassol J, Mange A, Pèlegrin A, Ozsahin M, Azria D. Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy.
Bourgier C, Lacombe J, Solassol J, Mange A, Pèlegrin A, Ozsahin M, Azria D. Crit Rev Oncol Hematol. 2015 Mar;93(3):312-9. Epub 2014 Nov 22. Review.

 

Mourah S, Denis MG, Narducci FE, Solassol J, Merlin JL, Sabourin JC, Scoazec JY, Ouafik L, Emile JF, Heller R, Souvignet C, Bergougnoux L, Merlio JP. Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting.
PLoS One. 2015 Mar 19;10(3):e0120232.  eCollection 2015.

 

Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA, Cohen PA. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Res. 2015 Jan 30;17(1):13.

 

Larive RM, Moriggi G, Menacho-Márquez M, Cañamero M, de Álava E, Alarcón B, Dosil M, Bustelo XR. Contribution of the R-Ras2 GTP-binding protein to primary breast tumorigenesis and late-stage metastatic disease. Nat Commun. 2014 May 14;5:3881.

 

Lacombe J, Mange A, Bougnoux AC, Prassas I, Solassol J: A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.

Cancer Epidemiol Biomarkers Prev 2014, 23(9):1834-1842

 

Lacombe J, Mange A, Jarlier M, Bascoul-Mollevi C, Rouanet P, Lamy PJ, Maudelonde T, Solassol J: Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. Int J Cancer 2013, 132(5):1105-1113

 

Vilquin P, Villedieu M, Grisard E, Ben Larbi S, Ghayad SE, Heudel PE, Bachelot T, Corbo L, Treilleux I, Vendrell JA, Cohen PA.Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int J Cancer. 2013 Oct 1;133(7):1589-602.

 

Lacombe J, Azria D, Mange A, Solassol J: Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes. Expert Rev Proteomics 2013, 10(1):33-42

 

Belguise K, Milord S, Galtier F, Moquet-Torcy G, Piechaczyk M, Chalbos D. The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells. Oncogene. 2012 Nov 22;31(47):4889-97. doi: 10.1038/onc.2011.659.

 

Larive RM, Abad A, Cardaba CM, Hernández T, Cañamero M, de Álava E, Santos E, Alarcón B, Bustelo XR. The Ras-like protein R-Ras2/TC21 is important for proper mammary gland development. Mol Biol Cell. 2012 Jun;23(12):2373-87.

 

Bougnoux A, Mange A, Solassol J: Proteomic analysis of differently archived breast cancer tissues. Cancer genomics & proteomics 2012, 9(2):93-99

 

Romagnoli M, Belguise K, Yu Z, Wang X, Landesman-Bollag E, Seldin DC, Chalbos D, Barillé-Nion S, Jézéquel P, Seldin ML, Sonenshein GE. Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5. Cancer Res. 2012; 72(23); 6268–78.

 

Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, and Eisenhauer EA  Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst, 2010 102, 1547-1556

 

Desmetz C, Mange A, Maudelonde T, Solassol J: Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med 2011.Oct;15(10):2013-24

 

Freiss G, Chalbos D. PTPN13/PTPL1: An Important Regulator of Tumor Aggressiveness. Anticancer Agents Med Chem. 2011 Jan 1;11(1):78-88.

 

Solassol J, Rouanet P, Lamy PJ, Allal C, Favre G, Maudelonde T, Mange A: Serum protein signature may improve detection of ductal carcinoma in situ of the breast. Oncogene 2010, 29(4):550-560

Beaujouin M., Prébois C., Derocq D., Laurent-Matha V., Masson O., Pattingre S., Coopman P., Bettache N., Grossfield J., Hollingsworth R., Zhang H., Yao Z., Hyman B., Van Der Geer P., Smith G., and Liaudet-Coopman E. Pro-cathepsin D interacts with the extracellular domain of LRP1beta chain and promotes LRP1-dependent fibroblast outgrowth. J Cell Sci. 2010. 123:3336-3346.

 

Rochefort H., Chalbos D; The role of sex steroid receptors on lipogenesis in breast and prostate carcinogenesis: a viewpoint.Horm Cancer. 2010 Apr;1(2):63-70

 

Larive R., Urbach S, Poncet J., Jouin P., Mascré G., Sahuquet A., Mangeat P., Coopman P*. and Bettache N*. Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion. Oncogene. 2009. 28(24):2337-47

 

Mangé A, Chaurand P, Perrochia H, Roger P, Caprioli RM, Solassol J.Liquid chromatography-tandem and MALDI imaging mass spectrometry analyses of RCL2/CS100-fixed, paraffin-embedded tissues: proteomics evaluation of an alternate fixative for biomarker discovery. J Proteome Res. 2009 Dec;8(12):5619-28.

 

Glondu-Lassis M, Dromard M, Chavey C, Puech C, Fajas L, Hendriks W, Freiss G. Downregulation of protein tyrosine phosphatase PTP-BL represses adipogenesis. Int J Biochem Cell Biol. 2009 Nov;41(11):2173-80

 

Solassol J, Mange A: Identification of serum melanoma progression biomarkers through proteomic-based approaches. Expert Rev Proteomics 2009, 6(4):341-343

 

Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy PJ, Kramar A, Rouanet P, Maudelonde T, Mangé A, Solassol J. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res. 2009 Jul 15;15(14):4733-41.

 

Ndlovu N, Van Lint C, Van Wesemael K, Callebert P, Chalbos D, Haegeman G, Vanden Berghe W. Hyperactivated NF-{kappa}B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells. Mol Cell Biol. 2009 Oct;29(20):5488-504

 

Wang X, Belguise K, O'Neill CF, Sánchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C, Trinkaus-Randall V, Chalbos D, Sonenshein GE. RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein

Blimp1.Mol Cell Biol. 2009 Jul;29(14):3832-44

 

Révillion F, Puech C, Rabenoelina F, Chalbos D, Peyrat JP, Freiss G. Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independentprognostic marker for overall survival in breast cancer. Int J Cancer. 2009 Feb 1;124(3):638-43

 

Bonnet, J., Coopman, P. and Morris, M. C. Characterization of centrosomal localization and dynamics of Cdc25C phosphatase in mitosis. Cell Cycle, 2008. 7:1991-8.

 

Dromard M, Bompard G, Glondu-Lassis M, Puech C, Chalbos D, Freiss G. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res. 2007 Jul 15;67(14):6806-13

 

Lanvin O, Bianco S, Kersual N, Chalbos D, Vanacker JM. Potentiation of ICI182,780 (Fulvestrant)-induced estrogen receptor-alpha degradation by the estrogen receptor-related receptor-alpha inverse agonist XCT790. J Biol Chem. 2007 Sep 28;282(39):28328-34.

 

Basbous J, Chalbos D, Hipskind R, Jariel-Encontre I, Piechaczyk M. Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol Cell Biol. 2007 Jun;27(11):3936-50.

 

Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D, Sonenshein GE. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol. 2007 Apr;9(4):470-8.

 

Esslimani-Sahla M, Thezenas S, Simony-Lafontaine J, Kramar A, Lavaill R, Chalbos D, Rochefort H. Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. Int J Cancer. 2007 Jan 15;120(2):224-9.

 

Coopman P. and Mueller, S. The Syk tyrosine kinase: a new negative regulator in tumor growth and progression. Cancer Lett., 2006, 241:159-73.

 

Bompard G, Sharp SJ, Freiss G, Machesky LM. Involvement of Rac in actin cytoskeleton rearrangements induced by MIM-B. J Cell Sci. 2005 Nov 15;118(Pt 22):5393-403

 

Freiss G, Galtier F, Puech C, Aknin C, Maudelonde T, Chalbos D, Vignon F. Anti-growth factor activities of benzothiophenes in human breast cancer cells. J Steroid Biochem Mol Biol. 2005 Apr;94(5):451-60.

 

Zyss, D., Montcourrier, P., Vidal, B., Anguille, C., Merezegue, F., Sahuquet, A., Mangeat, P. and Coopman, P. The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression. Cancer Res 2005  65: 10872-80

 

Belguise K, Kersual N, Galtier F, Chalbos D.FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene. 2005 Feb 17;24(8):1434-44.

 

Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk E, Blancato JK, Vezza PR, McLeskey SW, Mangeat PH, Mueller SC. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature. 2000 Aug 17;406(6797):742-7.


 

 

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Conception : ID Alizés